Australia's largest stock trading and investment forum Australia's #1 stock forum

HHI

0.00%

0.5¢ health house international limited

Ann: New SME Pricing, page-151

First 151 Last

Share
Profile

Follow
chris1983

13,667 Posts.

1290

24/06/16

12:40

Post #: 18112232
Share

Originally posted by nine lives ↑

I had to go out this morning and just got back and found out that I have to go out again. I posted then modded my own post this morning because I don't want to be misinterpreted. Unfortunately I don't have time right now to craft the post that I wanted to make so I simply say this.......I see a speed bump dead ahead....not a road block, just a speed bump. Last night Chris1983 made three points. One was the competition by RFN will hurt VPC. The second was in regards to past revenue and cash burn and the third was the possibility of an upcoming CR. The first two points I have already dismissed out of hand....the third point made by Chris has become more of a worry than it was a week ago. That news on the 15th was not good news....it was bad news. Not company destroying bad news but speed bump bad news. The first Ballieu report back in Jan stated that Ballieu believed that with the sales team in place 20% month on month was achievable. They didn't say it was happening but said it was achievable. In the report on the 15th they don't mention this but make mention of the fact that enterprise customers were increasing at a rate of about 15% month on month. Russell confirmed this the next day in his letter to shareholders that the increase was about 14% month on month. 14% month on month is very healthy imho and not to be sneezed at......but it is not 20% and one now wonders whether they can make it through without a second round of fund raising. If you sit down and do a calc and compare 15% and 20% month on month you will find that at the end of one year revenue earnings for 15% will be about 60% of what they would be for 20%. Whilst neither Ballieu nor Russell have come out and stated that 20% won't be achieved Ballieu have adjusted their revenue predictions for this year quite dramatically downwards....ie to 60% of what they said in January.....so without spelling it out they are saying with their numbers that they are now working on 15% month on month and NOT 20%. This still does not necessarily mean another CR but it certainly means a heightened risk of a CR. Someone here mentioned that they were doing broker presentations in Melbourne last week. That made me worry a little bit....why would you be doing a broker preso in you were not looking to place stock?? If there has to be a CR then I hope it is done quickly and at a good price. An announcement after the event telling us that stock was placed with an insto would suit me fine. That would remove the cause of worry. I think VPC is doing really well but I think they may have set themselves high goals for client signing to avoid a second CR. Maybe the going is just a bit slower than they thought it would be.

View attachment 157992

Expand

Just to bump this thread VPC should be considered post June 30 for an entry. One to keep an eye on. I think they have a market to tap into and still have a good business. The raising was always potentially on the cards.

VPC Price at posting: 2.9¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

First 151 Last

Add HHI (ASX) to my watchlist

Ann: New SME Pricing, page-151

Top Stories

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Zeta Resources seeks to resolve the Panoramic takeover story

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News